Innovate, Involve, Inspire: Preventing Hepatitis C Through Community-Led Harm Reduction (HEPC III)
Innovate, Involve, Inspire: Preventing Hepatitis C Through Community-Led Harm Reduction (HEPC III)
Alliance for Public Health is part of a new four-year program (2023-2026) that will build evidence of effective hepatitis C treatments and increase the uptake and scale up of community-led programs to reduce Hepatitis C infections in three countries.
The program, led by Frontline AIDS, with funding from UNITAID, aims to reduce new hepatitis C infections amongst people who use drugs. The innovations made through this new program could significantly reduce the transmission of hepatitis C and HIV.
The program is implemented with partners in Egypt, Kyrgyzstan and Nigeria who – with technical support of APH – will research the effectiveness and acceptability of under-used hepatitis C prevention innovations with people who use drugs:
- Providing Long-Acting Buprenorphine (LAB): a new form of Opioid Agonist Treatment (OAT) which is released slowly into the body to maintain treatment of opioid dependence.
The countries of this study are Egypt and Kyrgyzstan.
- Hepatitis C testing and treatment in community harm reduction settings.
The countries of this study are Egypt, Kyrgyzstan and Nigeria.
Project implementation period: 2023 – 2026
Total project budget: 2 875 000 USD
Project Manager: Anna Meteliuk, meteliuk@aph.org.ua
Photo gallery: working meetings with representatives of the Ministries of Health of Egypt and Kyrgyzstan, visits to the sites of interventions within the project.
